{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:22:35Z","timestamp":1767612155144,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.cllc.2020.10.005","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T12:52:42Z","timestamp":1602679962000},"page":"142-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol"],"prefix":"10.1016","volume":"22","author":[{"given":"Rajiv","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura V.","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inn","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Fei\u00dft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8269-3821","authenticated-orcid":false,"given":"Marc A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.10.005_bib1","doi-asserted-by":"crossref","first-page":"2782590","DOI":"10.1155\/2017\/2782590","article-title":"Life expectancy in pleural and peritoneal mesothelioma","volume":"2017","author":"Shavelle","year":"2017","journal-title":"Lung Cancer Int"},{"key":"10.1016\/j.cllc.2020.10.005_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.cllc.2020.10.005_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/JTO.0b013e3181f1903e","article-title":"Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population","volume":"5","author":"Flores","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A\u00a0systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.10.005_bib5","doi-asserted-by":"crossref","first-page":"102815","DOI":"10.1016\/j.critrevonc.2019.102815","article-title":"Emerging therapies in malignant pleural mesothelioma","volume":"144","author":"Cinausero","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2020.10.005_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2020.10.005_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2020.10.005_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ejcts\/ezs418","article-title":"Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience","volume":"43","author":"Ried","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2020.10.005_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","article-title":"Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection","volume":"145","author":"Sugarbaker","year":"2013","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2020.10.005_bib13","first-page":"301","article-title":"[Implementation of hyperthermic intrathoracic chemotherapy (HITHOC) in Germany]","volume":"143","author":"Ried","year":"2018","journal-title":"Zentralbl Chir"},{"key":"10.1016\/j.cllc.2020.10.005_bib14","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.21037\/jtd.2019.04.93","article-title":"Pleurectomy\/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma","volume":"11","author":"Klotz","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2020.10.005_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib16","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.21037\/jtd.2017.12.88","article-title":"New horizons from immunotherapy in malignant pleural mesothelioma","volume":"10","author":"Calabro","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2020.10.005_bib17","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"year":"2020","author":"Baas","series-title":"First-line nivolumab\u00a0+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743. Presented at the International Association for the Study of Lung Cancer WCLC 2020 Virtual Presidential Symposium, Singapore; August 8","key":"10.1016\/j.cllc.2020.10.005_bib20"},{"key":"10.1016\/j.cllc.2020.10.005_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.cllc.2020.10.005_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12254-018-0444-7","article-title":"ASCO 2018 NSCLC highlights\u2014combination therapy is key","volume":"11","author":"Gamerith","year":"2018","journal-title":"Memo"},{"key":"10.1016\/j.cllc.2020.10.005_bib23","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.10.005_bib24","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: a phase II study of durvalumab with first line chemotherapy in mesothelioma\u2014first results","volume":"36","author":"Nowak","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.cllc.2020.10.005_bib25","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","volume":"38","author":"Forde","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.10.005_bib26","first-page":"497","article-title":"Standardizing surgical treatment in malignant pleural mesothelioma","volume":"1","author":"Rice","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2020.10.005_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.20315","article-title":"Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma","volume":"101","author":"Hollen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2020.10.005_bib28","first-page":"11","article-title":"Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso","volume":"14","author":"Hollen","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cllc.2020.10.005_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:11:31Z","timestamp":1761505891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420303077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1525730420303077"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.10.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}